The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity

Cancer Research

Volumn 69, Issue 15, 2009, Pages 6208-6215

  Ali, Simak ^a   Heathcote, Dean A ^a   Kroll, Sebastian H B ^a   Jogalekar, Ashutosh S ^b   Scheiper, Bodo ^a   Patel, Hetal ^a   Brackow, Jan ^a   Siwicka, Alekasandra ^a   Fuchter, Matthew J ^a   Periyasamy, Manikandan ^a   Tolhurst, Robert S ^a   Kanneganti, Seshu K ^a   Snyder, James P ^b   Liotta, Dennis C ^b   Aboagye, Eric O ^a   Barrett, Anthony G M ^a   Coombes, R Charles ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BS 181; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLIN DEPENDENT KINASE 7; PYRAZOLO[1,5 A]PYRIMIDINE DERIVATIVE; ROSCOVITINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COMPUTER-AIDED DESIGN; CYCLIN-DEPENDENT KINASES; DRUG DESIGN; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 68049125103     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0301     Document Type: Article

References (37)

1. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-1677
2. Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 1997;13:261-291
3. Fisher RP. Secrets of a double agent: CDK7 in cellcycle control and transcription. J Cell Sci 2005;118: 5171-5180
4. Harper JW, Elledge SJ. The role of Cdk7 in CAK function, a retro-retrospective. Genes Dev 1998;12: 285-289
5. Lolli G, Johnson LN. CAK-Cyclin-dependent activating kinase: a key kinase in cell cycle control and a target for drugs? Cell Cycle 2005;4:572-577
6. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 2004;145:5439-5447 (Pubitemid 39564581)
7. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1: 222-231 (Pubitemid 33741897)
8. Knockaert M, Greengard P, Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 2002;23:417-425
9. Senderowicz AM. Small-molecule cyclin-dependent kinase modulators. Oncogene 2003;22:6609-6620
10. Benson C, White J, De Bono J, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007;96: 29-37. (Pubitemid 46094635)
11. Losiewicz MD, Carlson BA, Kaur G, Sausville EA, Worland PJ. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 1994;201:589-595 (Pubitemid 2089675)
12. McClue SJ, Blake D, Clarke R, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002;102:463-468
13. Raynaud FI, Whittaker SR, Fischer PM, et al. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclindependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res 2005;11:4875-4887
14. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004;18: 2699-2711
15. Malumbres M, Barbacid M. Mammalian cyclindependent kinases. Trends Biochem Sci 2005;30:630-641
16. Rossi DJ, Londesborough A, Korsisaari N, et al. Inability to enter S phase and defective RNA polymerase II CTD phosphorylation in mice lacking Mat1. EMBO J 2001;20:2844-2856 (Pubitemid 32938567)
17. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770-1783 (Pubitemid 46628473)
18. Fischer PM. The use of CDK inhibitors in oncology: a pharmaceutical perspective. Cell Cycle 2004;3:742-746
19. Pallas M, Verdaguer E, Jorda EG, Jimenez A, Canudas AM, Camins A. Flavopiridol: an antitumor drug with potential application in the treatment of neurodegenerative diseases. Med Hypotheses 2005;64:120-123 (Pubitemid 39469250)
20. Roy R, Adamczewski JP, Seroz T, et al. The MO15 cell cycle kinase is associated with the TFIIH transcription- DNA repair factor. Cell 1994;79:1093-1101
21. Serizawa H, Makela TP, Conaway JW, Conaway RC, Weinberg RA, Young RA. Association of Cdk-activating kinase subunits with transcription factor TFIIH. Nature 1995;374:280-282
22. Rochette-Egly C, Adam S, Rossignol M, Egly JM, Chambon P. Stimulation of RARa activation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK7. Cell 1997;90:97-107. (Pubitemid 28009422)
23. Chen D, Riedl T, Washbrook E, et al. Activation of estrogen receptor a by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Mol Cell 2000;6:127-137
24. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-1112 (Pubitemid 20213250)
25. Lopez-Garcia J, Periyasamy M, Thomas RS, et al. ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases. Nucleic Acids Res 2006;34:6126-6136 (Pubitemid 44942734)
26. Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004;47:1739-1749
27. Friesner RA, Murphy RB, Repasky MP, et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 2006;49:6177-6196
28. Zhang Y, Li M, Chandrasekaran S, et al. A unique quinolineboronic acid-based supramolecular structure that relies on double intermolecular B-N bonds for selfassembly in solid state and in solution. Tetrahedron 2007;63:3287-3292 (Pubitemid 46400783)
29. Williamson DS, Parratt MJ, Bower JF, et al. Structureguided design of pyrazolo[1,5-a]pyrimidines as inhibitors of human cyclin-dependent kinase 2. Bioorg Med Chem Lett 2005;15:863-867
30. Hong Y, Tanoury GJ, Wilkinson CJ, Bakale RP, Wald SA, Senanayake CH. Palladium catalyzed amination of 2- chloro-1,3-azole derivatives: mild entry to potent H-1- antihistaminic norastemizole. Tetrahedron Lett 1997;38: 5607-5610 (Pubitemid 27321134)
31. Sridhar J, Akula N, Pattabiraman N. Selectivity and potency of cyclin-dependent kinase inhibitors. AAPS J 2006;8:E204-21.
32. Lam LT, Pickeral OK, Peng AC, et al. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2001;2:RESEARCH0041.
33. Lu X, Burgan WE, Cerra MA, et al. Transcriptional signature of flavopiridol-induced tumor cell death. Mol Cancer Ther 2004;3:861-872 (Pubitemid 39193768)
34. Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 2005; 106:2513-2519 (Pubitemid 41510827)
35. Gartel AL. Transcriptional inhibitors, p53 and apoptosis. Biochim Biophys Acta 2008;1786:83-86
36. Bunz F, Fauth C, Speicher MR, et al. Targeted inactivation of p53 in human cells does not result in aneuploidy. Cancer Res 2002;62:1129-1133 (Pubitemid 34160298)
37. Gomes NP, Bjerke G, Llorente B, Szostek SA, Emerson BM, Espinosa JM. Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program. Genes Dev 2006;20: 601-612 (Pubitemid 43345325)